In a pair of new reports, nonprofit research group the Institute for Clinical and Economic Review (ICER) assessed the cost benefit analyses for oral therapies treating amyotrophic lateral sclerosis (ALS) and gene therapies for use against hemophilia.
Source: Drug Industry Daily